Work

Serum chemokines and cytokines in CLL patients treated with duvelisib, a PI3K-δ,γ inhibitor.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.7072

Authors: Mark Douglas, Kerstin Allen, Jennifer Sweeney, Susan Mary O'Brien, Ian Flinn, Steven M. Horwitz, John C. Byrd, Manish R. Patel, Brad S. Kahl, Francine M. Foss, Pierluigi Porcu, Virginia Kelly, Howard Stern

Institutions: Infinity Pharmaceuticals (United States), UC Irvine Health, UC Irvine Chao Family Comprehensive Cancer Center, Sarah Cannon, Tennessee Oncology, Memorial Sloan Kettering Cancer Center, The Ohio State University Wexner Medical Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Yale Cancer Center

Language: English

Topic: Chronic Lymphocytic Leukemia Research

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2597145840

Cites:

Cited by: 2

Related to: 10